SOUTH SAN FRANCISCO, Calif.,
Dec. 8, 2017 /PRNewswire/ -- Rigel
Pharmaceuticals (Nasdaq: RIGL) today announced that on December 4, 2017 the Compensation Committee of
Rigel's Board of Directors approved the grant of inducement stock
options to purchase an aggregate of 60,000 shares of common stock
to one new employee. This award was granted pursuant to the Rigel
Pharmaceuticals, Inc. Inducement Plan, as amended, as an inducement
material to the new employee entering into employment with Rigel,
in accordance with NASDAQ Listing Rule 5635(c)(4).
Rigel granted stock options to purchase shares of Rigel's common
stock to one employee with an exercise price of $4.09 per share, the closing price of Rigel's
common stock on December 1, 2017, the
first trading date prior to December 4,
2017, the effective date of such grant. The stock options
vest as follows: certain of the shares of common stock subject to
the award vest over a four year period, with one-fourth of the
shares subject to such awards vesting on the first anniversary of
the award's vesting commencement date, and the remaining shares
vesting in equal monthly installments thereafter, and certain of
the shares of common stock subject to the award vest immediately
upon achievement of one or more performance conditions.
Rigel is providing this information in accordance with NASDAQ
Listing Rule 5635(c)(4).
About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated
to discovering, developing and providing novel small molecule drugs
that significantly improve the lives of patients with immune and
hematological disorders, cancer and rare diseases. Rigel's
pioneering research focuses on signaling pathways that are critical
to disease mechanisms. The company's current clinical programs
include clinical trials of fostamatinib, an oral spleen tyrosine
kinase (SYK) inhibitor, in a number of indications. Rigel has
submitted, and the FDA has accepted for review, an NDA for
fostamatinib in patients with chronic or persistent immune
thrombocytopenia (ITP). In addition, Rigel has product candidates
in development with partners BerGenBio AS, Daiichi Sankyo and
Aclaris Therapeutics.
Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com
View original
content:http://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grant-under-nasdaq-listing-rule-5635c4-300569160.html
SOURCE Rigel Pharmaceuticals, Inc.